⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 3, 2024Open Access

Supplementary Figure S2 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (²²⁵Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S2. PSMA expression in CDX and PDX prostate cancer xenograft models as determined via IHC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schatz et al. (2024) studied this question.

synapsesocial.com/papers/68e66839b6db6435875f3db3 https://doi.org/10.1158/1078-0432.25956511.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer2024
2Supplementary Figure S7 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer2024
3Supplementary Figure S7 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer2024
4Supplementary Figure S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer2024
5Supplementary Figure S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer2024